Abstract
Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative radiotherapy (RT) or concurrent chemoradiotherapy. Materials and Methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival was analyzed in 35 patients. Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5%) experienced treatment failure. Fifteen patients (27%) had local failure: nine (16%) local failure only, three (5%) locoregional failure, two (4%) local and distant failure, and one (2%) locoregional and distant failure. Of 56 patients, seven (13%) had persistent disease at the first follow-up at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6% and 44.0%, respectively. In multivariate analysis, clinical size ≥3 cm predicted a poor prognostic factor for DFS (p = 0.040) and age (≥70 years) was poor prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but the differences were not significant statistically. Conclusion: Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ≥70 years.
| Original language | English |
|---|---|
| Pages (from-to) | 198-206 |
| Number of pages | 9 |
| Journal | Radiation Oncology Journal |
| Volume | 33 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2015 Jan 1 |
Fingerprint
Keywords
- Radiotherapy
- Risk factor
- Survival
- Vulvar cancer
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
Cite this
Treatment outcomes of curative radiotherapy in patients with vulvar cancer : Results of the retrospective KROG 1203 study. / Kim, Youngkyong; Kim, Joo Young; Kim, Ja Young; Lee, Nam Kwon; Kim, Jin Hee; Kim, Yong Bae; Kim, Young Seok; Kim, Juree; Kim, Yeon Sil; Yang, Dae-Sik; Kim, Yeon Joo.
In: Radiation Oncology Journal, Vol. 33, No. 3, 01.01.2015, p. 198-206.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment outcomes of curative radiotherapy in patients with vulvar cancer
T2 - Results of the retrospective KROG 1203 study
AU - Kim, Youngkyong
AU - Kim, Joo Young
AU - Kim, Ja Young
AU - Lee, Nam Kwon
AU - Kim, Jin Hee
AU - Kim, Yong Bae
AU - Kim, Young Seok
AU - Kim, Juree
AU - Kim, Yeon Sil
AU - Yang, Dae-Sik
AU - Kim, Yeon Joo
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative radiotherapy (RT) or concurrent chemoradiotherapy. Materials and Methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival was analyzed in 35 patients. Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5%) experienced treatment failure. Fifteen patients (27%) had local failure: nine (16%) local failure only, three (5%) locoregional failure, two (4%) local and distant failure, and one (2%) locoregional and distant failure. Of 56 patients, seven (13%) had persistent disease at the first follow-up at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6% and 44.0%, respectively. In multivariate analysis, clinical size ≥3 cm predicted a poor prognostic factor for DFS (p = 0.040) and age (≥70 years) was poor prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but the differences were not significant statistically. Conclusion: Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ≥70 years.
AB - Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative radiotherapy (RT) or concurrent chemoradiotherapy. Materials and Methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival was analyzed in 35 patients. Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5%) experienced treatment failure. Fifteen patients (27%) had local failure: nine (16%) local failure only, three (5%) locoregional failure, two (4%) local and distant failure, and one (2%) locoregional and distant failure. Of 56 patients, seven (13%) had persistent disease at the first follow-up at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6% and 44.0%, respectively. In multivariate analysis, clinical size ≥3 cm predicted a poor prognostic factor for DFS (p = 0.040) and age (≥70 years) was poor prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but the differences were not significant statistically. Conclusion: Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ≥70 years.
KW - Radiotherapy
KW - Risk factor
KW - Survival
KW - Vulvar cancer
UR - http://www.scopus.com/inward/record.url?scp=84944074784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944074784&partnerID=8YFLogxK
U2 - 10.3857/roj.2015.33.3.198
DO - 10.3857/roj.2015.33.3.198
M3 - Article
AN - SCOPUS:84944074784
VL - 33
SP - 198
EP - 206
JO - Radiation Oncology Journal
JF - Radiation Oncology Journal
SN - 2234-1900
IS - 3
ER -